New combo therapy targets hard-to-treat head and neck cancer

NCT ID NCT06194656

Recruiting now Disease control Sponsor: Shanghai Institute Of Biological Products Source: ClinicalTrials.gov ↗

First seen Jan 19, 2026 · Last updated Apr 30, 2026 · Updated 16 times

Summary

This study tests a new drug called SIBP-03 combined with cetuximab in people with advanced head and neck cancer that has returned or spread. The goal is to see if the combination can shrink tumors or slow the disease. About 81 adults aged 18-75 who have already tried immunotherapy and platinum chemotherapy are eligible. The study focuses on safety and how well the treatment works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shanghai East Hospital
RECRUITING

Shanghai, Shanghai Municipality, China
Shanghai East Hospital
RECRUITING

Shanghai, Shanghai Municipality, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Contact

Conditions

Explore the condition pages connected to this study.

HEAD AND NECK SQUAMOUS CELL CARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA